Last reviewed · How we verify
Single-dose Quadrivalent Influenza Vaccine
Single-dose Quadrivalent Influenza Vaccine is a Influenza vaccine Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 3 development for Prevention of influenza disease caused by four different strains of the influenza virus. Also known as: VaxigripTetra.
This vaccine induces an immune response against four different influenza viruses.
This vaccine induces an immune response against four different influenza viruses. Used for Prevention of influenza disease caused by four different strains of the influenza virus.
At a glance
| Generic name | Single-dose Quadrivalent Influenza Vaccine |
|---|---|
| Also known as | VaxigripTetra |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The quadrivalent influenza vaccine contains inactivated viruses that stimulate the body's immune system to produce antibodies and immune cells that can recognize and fight the viruses. This immune response helps to protect against influenza infection.
Approved indications
- Prevention of influenza disease caused by four different strains of the influenza virus
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
- Muscle pain
- Fever
Key clinical trials
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
- A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults (PHASE2)
- Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae (PHASE2)
- Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection (PHASE4)
- Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older (PHASE1)
- Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults (PHASE1)
- A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Single-dose Quadrivalent Influenza Vaccine CI brief — competitive landscape report
- Single-dose Quadrivalent Influenza Vaccine updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI
Frequently asked questions about Single-dose Quadrivalent Influenza Vaccine
What is Single-dose Quadrivalent Influenza Vaccine?
How does Single-dose Quadrivalent Influenza Vaccine work?
What is Single-dose Quadrivalent Influenza Vaccine used for?
Who makes Single-dose Quadrivalent Influenza Vaccine?
Is Single-dose Quadrivalent Influenza Vaccine also known as anything else?
What drug class is Single-dose Quadrivalent Influenza Vaccine in?
What development phase is Single-dose Quadrivalent Influenza Vaccine in?
What are the side effects of Single-dose Quadrivalent Influenza Vaccine?
Related
- Drug class: All Influenza vaccine drugs
- Manufacturer: Sanofi Pasteur, a Sanofi Company — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of influenza disease caused by four different strains of the influenza virus
- Also known as: VaxigripTetra
- Compare: Single-dose Quadrivalent Influenza Vaccine vs similar drugs
- Pricing: Single-dose Quadrivalent Influenza Vaccine cost, discount & access